Epiminder

Epilepsy is a complex neurological condition affecting over 50 million people globally, with a significant part of the patient population not responding to traditional medication. Epilepsy not only imposes chronic, debilitating effects but also subjects patients to the unpredictable nature of when and how seizures might occur. Epiminder Limited is revolutionising epilepsy care with its implantable continuous EEG monitoring (iCEM®) system, the Minder® system. Minder has been granted authorization via the FDA's de novo pathway and is building a commercial presence in the US. Seizure diaries are often unreliable, the true picture of a patient's condition may be different from what it initially appears. This creates gaps in understanding of what treatments should be deployed to address the patient’s underlying condition. The Minder system will address this gap by unveiling continuous and objective EEG data that would not otherwise been seen. Like other diagnostic devices used in conditions requiring continuous monitoring of physiological signals (e.g. implantable cardiac monitors and continuous glucose monitors), the Minder system represents a significant leap forward in epilepsy care, providing objective insights that enable informed clinical actions. Headquartered in Melbourne, Australia, with an office in Dallas, TX, USA, Epiminder is a public company dedicated to advancing neurological health.